NCT06714253: An ongoing trial by RiboX Therapeutics Ltd.
This trial is ongoing. It must report results 2 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06714253 |
|---|---|
| Title | A Phase I/IIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults With Radiation-Induced Xerostomia and Hyposalivation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 5, 2025 |
| Completion date | Aug. 31, 2027 |
| Required reporting date | Aug. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |